



ASX ANNOUNCEMENT

DATE OF ANNUAL GENERAL MEETING

SYDNEY, Tuesday 13 September 2016, Cellmid Limited (ASX: CDY).

In accordance with ASX Listing Rule 3.13.1 and Clause 46.3 of its Constitution, Cellmid Limited advises that the Annual General Meeting will be held at 11am on Monday, 21 November 2016 at BDO Offices, Level 11, 1 Margaret Street, Sydney NSW 2000.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programmes in multiple disease indications. The Company is developing innovative novel therapies and diagnostic tests for cancer and inflammatory diseases. Through its wholly owned subsidiaries, Advangen Limited and Advangen Inc., Cellmid also develops and sells FGF5 inhibitor hair loss products. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au and www.evolisproducts.com.au.